- Home
- FGNX vs NRXS Comparison
FGNX vs NRXS Comparison
Compare FGNX & NRXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | FGNX | NRXS |
|---|---|---|
| Founded | 1932 | 2011 |
| Country | United States | United States |
| Employees | 130 | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.5M | 46.3M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | FGNX | NRXS |
|---|---|---|
| Price | $7.03 | $6.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $36.50 | $8.00 |
| AVG Volume (30 Days) | ★ 137.7K | 113.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 72.89 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,685,925.00 |
| Revenue This Year | $95.83 | $31.05 |
| Revenue Next Year | $42.41 | $146.31 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 9.18 |
| 52 Week Low | $1.59 | $1.33 |
| 52 Week High | $18.42 | $6.35 |
Technical Indicators
Market Signals| Indicator | FGNX | NRXS |
|---|---|---|
| Relative Strength Index (RSI) | 59.25 | 68.45 |
| Support Level | $5.43 | $2.32 |
| Resistance Level | $9.35 | N/A |
| Average True Range (ATR) | 0.51 | 0.46 |
| MACD | -0.12 | 0.04 |
| Stochastic Oscillator | 21.94 | 95.50 |
Price Performance
Historical ComparisonAbout FGNX Fundamental Global Inc.
FG Nexus Inc is a capital markets platform focused on long-term Ethereum (ETH) accumulation and on-chain yield generation. The company provides institutional investors with secure, regulated access to ETH as a productive reserve asset, generating native staking yield while underpinning stablecoins, tokenized assets, and AI-driven applications.
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).